Stem cell gene therapy: selecting only the best

November 14, 2003

Curing human diseases using gene transfer into human hematopoietic stem cells (HSCs) remains a promising avenue for development. In the November 14 issue of the Journal of Clinical Investigation, two independent studies - the first by Stanton Gerson and colleagues at Case Western University and the second by Hans-Peter Kiem and colleagues at the Fred Hutchinson Cancer Research Center - have accomplished, for the first time, the selection and expansion of gene-corrected HSCs from large animals (dogs and humans), using a novel drug-resistance gene, MGMT.

Highly efficient transfer and expression of MGMT into relatively few HSCs using a lentivirus vector led to repopulation of the hematopoietic compartment with gene-corrected cells following suitable drug treatment. This selection system may be useful in human clinical trials of gene therapy in bone marrow transplantation settings.

In an accompanying commentary, Arthur Bank from Columbia University College of Physicians and Surgeons discusses the potential of these results in significantly advancing our knowledge and ability to perform human HSC gene therapy.
-end-
TITLE: In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning

AUTHOR CONTACT:
Stanton L. Gerson
Case Western Reserve University, Cleveland, Ohio, USA.
Phone: 216-368-1177
Fax: 216-368-1166
E-mail: slg5@po.cwru.edu

View the PDF of this article at: http://www.jci.org/cgi/content/full/112/10/1561

RELATED ARTICLE:

TITLE: Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model

AUTHOR CONTACT:
Hans-Peter Kiem
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Phone: 206-667-4425
Fax: 206-667-6124
E-mail: hkiem@fhcrc.org

View the PDF of this article at: http://www.jci.org/cgi/content/full/112/10/1581

ACCOMPANYING COMMENTARY:
Hematopoietic stem cell gene therapy: selecting only the best

AUTHOR CONTACT:
Arthur Bank
Columbia University, New York, New York, USA.
Phone: 212-305-4186
Fax: 212-923-2090
E-mail: ab13@columbia.edu

JCI Journals

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.